8-5. SPECIFIC ANTICONVULSANT DRUGS
a. Phenobarbital.
(1) Clinical uses. Phenobarbital is orally administered in the treatment of grand mal epilepsy. It is less effective in the treatment of petit mal and psychomotor epilepsy. The injectable from of the drug is used to treat other types of convulsions.
(2) Adverse effects. The most common adverse effects associated with phenobarbital are related to sedation and disinhibition (see lesson 7 of this subcourse). These include dizziness, drowsiness, ataxia (lack of muscular coordination), and nystagmus (a rapid involuntary movement of the eyeball). Furthermore, as discussed in lesson 7 of this subcourse, persons taking phenobarital can experience withdrawal symptoms when they suddenly stop taking the drug. Epileptic patients are unusually susceptible to the hyperexcitable state induced by too rapid reduction of dosage or too rapid withdrawal of phenobarbital.
(3) Cautions and warnings. Patients who take phenobarbital should be warned about drowsiness. Patients who take phenobarbital should not drink alcohol while taking phenobarbital. Dosage of the drug should be reduced by small amounts in order to avoid hastening convulsions. Lastly, phenobarbital may stimulate the activity of a number of enzyme systems and affect the metabolism of various drugs (for example, anticoagulants, phenytoin).
b. Phenytoin (DilantinÒ).
(1) Clinical uses. Phenytoin is used alone or in combination with phenobarbital in the treatment of grand mal and psychomotor epilepsy. It is also used in the treatment of other types of convulsions.
(2) Adverse effects. Adverse effects associated with phenytoin include ataxia (lack of muscular coordination, staggering walk), nystagmus (a rapid, involuntary movement of the eyeball), and slurred speech. Drowsiness and fatigue may accompany these adverse effects in some patients by tremors and nervousness and in others.
(3) Caution and warning. Drug interactions can occur between phenytoin and alcohol, barbiturates, folic acid, coumarin-type anticoagulants, disulfirams, the sulfonamides, and sympathomimetic agents. Phenytoin should be used cautiously with patients who are alcoholics or who have blood dyscrasias.
c. Ethosuximide (Zarontin®).
(1) Clinic use. Ethosuxamide is the drug of first choice for the treatment of petit mal epilepsy.
(2) Adverse effects. Drowsiness, ataxia, and gastrointestinal irritation are adverse effects associated with the use of ethosuxamide.
(3) Caution and warning. Ethosuxamide should be used cautiously with patients who have blood dyscrasias or liver or kidney impairment.
d. Clonazepam (Klonopin®).
(1) Clinical uses. Clonazepam is used in the treatment of grand mal epilepsy. It is the alternate drug for the treatment of petit mal in patients who fail to respond to ethosuxamide (Zarontin®) therapy.
(2) Adverse effects. The primary side effect associated with clonazepam is central nervous system depression. Drowsiness is frequently seen in patients who take this medication.
e. Diazepam (Valium®), lorazepam (Ativan®).
(1) Clinical uses. Diazepam or lorazepam are drugs of first choice for the treatment of status epilepticus (a particular type of convulsive disorder) when it is given intravenously.
(2) Adverse effects. Drowsiness, fatigue, and ataxia are the most common adverse effects seen with diazepam.
NOTE: Midazolam (Versed®) may be used as a continuous infusion for the treatment of status epilepticus in patients that fail diazepam or lorazepam.